Sable Bio
Category: AI in Healthcare
An AI-powered platform that automates Target Safety Assessments (TSAs) to identify and mitigate toxicology risks early in the drug discovery process. Sable Bio was founded in 2023. The company is led by Josh Almond-Thynne. Based in London, United Kingdom. Team size: 13-15. Total funding raised: $5.7M. Latest round: Seed. Key investors include ["MMC Ventures","Episode 1 Ventures","Seedcamp","Episteme VC","SOSV","Martlet Capital"].
- Founded
- 2023
- Headquarters
- London, United Kingdom
- Team size
- 13-15
- Total funding
- $5.7M
Value proposition
Reduces the high rate of clinical trial failures by providing systematic, quantified safety insights at the target selection stage, transforming a traditionally manual, months-long process into an automated, data-driven workflow.
Products and solutions
["Sable Target Intelligence Platform","Automated Target Safety Assessment (TSA) Reports","Predictive Toxicology Engine","Unified Safety Data Aggregator (Genetic, Experimental, and Clinical data)"]
Unique value
Specifically targets the 'safety gap' in drug discovery by using LLMs to synthesize fragmented biomedical literature and multi-omic data into actionable, interpretable safety scores.
Target customer
Biotechnology companies, pharmaceutical R&D departments, toxicologists, and computational biologists.
Industries served
["Biotechnology","Pharmaceuticals","Healthcare AI","Life Sciences"]
Technology advantage
Combines Large Language Models (LLMs) with causal inference and deep biological data knowledge to extract proprietary signals and predict clinical side effects before drugs enter human trials.
How they differentiate
Sable Bio focuses specifically on the 'safety gap' by automating Target Safety Assessments (TSAs). While others focus on target discovery or molecule generation, Sable uses LLMs to synthesize fragmented multi-omic data and biomedical literature into quantified toxicology risk scores, turning a manual 3-6 month process into an automated workflow.
Main competitors
["Causaly","Insilico Medicine (PandaOmics)","BenevolentAI"]
Key partnerships
["MMC Ventures (Lead Investor)","Episode 1 Ventures","Seedcamp","Actively seeking R&D collaborations with mid-to-large cap pharmaceutical and healthtech firms"]
Notable customers
["Multiple top-ten global pharma firms","Biotech companies","Investment groups"]
Major milestones
["Company founded in January 2023 by former BenevolentAI leaders","Closed £1.5M Pre-seed round in February 2024","Launched the Sable Target Intelligence Platform for automated TSA reporting","Secured $3.75M Seed funding in October 2024 to scale the engineering and biology teams","Secured commercial agreements with multiple pharma companies including three top-ten global firms","Generated $0.5M in revenue in past twelve months","Publicly announced Seed round in February 2026"]
Growth metrics
Team grew to approximately 15 employees; generated $0.5M in revenue in past twelve months; secured commercial agreements with three top-ten global pharma firms.
Market positioning
Specialized AI-Biotech SaaS provider focusing on early-stage R&D risk mitigation and predictive toxicology.
Geographic focus
United Kingdom (HQ), Europe, and North America (Primary pharmaceutical R&D hubs).
Patents and IP
No specific public patents disclosed; relies on proprietary algorithms and data integration frameworks.
About Josh Almond-Thynne
Josh Almond-Thynne is the Co-Founder and CEO of Sable Bio. Prior to founding Sable, he helped deliver two pre-clinical candidates at BenevolentAI as a medicinal chemist. He pioneered the use of unstructured data in medicinal chemistry. He holds a PhD in organic chemistry from Imperial College London, and has held research positions at the University of Oxford, CSIRO, and Boehringer Ingelheim.
Official website: https://sablebio.com/